Skip to main content

Menu

British National Formulary December 2024 Update

This update contains 3 significant changes, 4 dose changes, 5 new monographs, 2 new preparations, and 2 deleted preparations.

Significant Changes:

  • Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation [MHRA/CHM advice].
  • Methenamine hippurate: updated prescribing information.
  • Urinary-tract infections: updated guidance for the prophylaxis of recurrent urinary tract infections.

Dose Changes:

  • Epipen® auto-injector 0.3 mg (adrenaline/epinephrine) [update to body-weight ranges].
  • Epipen® Jr auto-injector 0.15 mg (adrenaline/epinephrine) [update to body-weight ranges].
  • Jext® 150 micrograms (adrenaline/epinephrine) [update to body-weight ranges].
  • Jext® 300 micrograms (adrenaline/epinephrine) [update to body-weight ranges].

New Monographs:

  • Emblaveo® [aztreonam with avibactam].
  • Korserdu® [elacestrant].
  • Leqembi® [lecanemab].
  • Truqap® [capivasertib].
  • Vyloy® [zolbetuximab].

New Preparations:

  • Lecigon® [levodopa with carbidopa and entacapone].
  • Velariq® [oxybutynin hydrochloride].

Deleted Preparations:

  • Emerade® 300 micrograms [adrenaline/epinephrine].
  • Emerade® 500 micrograms [adrenaline/epinephrine].